Jacqueline Claudia Barrientos, MD
Ibrutinib (Imbruvica) has significantly changed the treatment landscape for patients with chronic lymphocytic leukemia (CLL). However, researchers have hope for another BTK inhibitor, acalabrutinib (Calquence), and are investigating the regimens in a head-to-head phase III study (NCT02477696; ACE-CL-006).
, Barrientos, an associate professor at The Feinstein Institute for Medical Research at Northwell Health, discussed emerging treatment options in CLL.
OncLive: What is the excitement with acalabrutinib? What potential could this have for patients with CLL?
There was a trial that was presented at the 2016 ASH Annual Meeting for patients who no longer take ibrutinib because they have intolerance. That is one of the approaches to take with this regimen. It would be off-label because there is no current FDA approval for CLL yet. However, ibrutinib was first approved in mantle cell lymphoma (MCL), then the approval came for patients with CLL who harbored a 17p deletion, followed by a full approval for relapsed/refractory patients with CLL, and then in the frontline setting. My guess is that it will be the same for acalabrutinib.
... to read the full story